AMGNAmgen

Healthcare

$414.93+54% 1Y

$414.93

$265.4052 weeks$444.20

Is the price fair?

Fair

Neither cheap nor expensive: modest expectations priced in, but at the top of its own P/E range.

1 good, 1 to watch, 1 neutral

What the price assumes~+4% a year

Priced for ~4% a year FCF growth. The price demands less than its three-year revenue growth of 13% a year, expectations look modest.

Vs its own P/E rangedearer than 78% of its own historyderived

Expensive vs its own history: P/E 25.8 vs a 18.2 median over 41 quarters (+41% vs median).

Vs sector (EV/EBIT)19.7×

Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Unless marked, from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)middle of the market

FCF yieldmiddle of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What AMGN's price assumes

Amgen trades at 25.8× earnings against 26.2× for the median Drug Manufacturers - General name, cheaper than its own group.

25.8

Trailing P/E · Drug Manufacturers - General median 26.2 · cheaper than the typical name in its group

Price / sales: 4.78
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 5.6%
Free cash flow yield · Drug Manufacturers - General median 5.7%
Growth the price implies: +4.2%
Growth the price implies · The price pays for +4.2% free cash flow growth a year for a decade; the business has delivered +1.7% a year over the last three.

Details›

Price / booktoday's price, trailing year to Jun 30, 2026: 15.6
EV / EBITtoday's price, trailing year to Jun 30, 2026: 19.7
EV / salestoday's price, trailing year to Jun 30, 2026: 5.92
Healthcare median P/E509 names: 26.2
Drug Manufacturers - General median P/E16 names: 26.2
Free cash flow, trailing twelve months: $10.2B
Market capitalisation: $182.2B
3-year revenue growth: +13%
3-year free cash flow growth: +1.7%

What the market has paid for these earnings: 41 quarters of its own multiple × $16.10 of trailing earnings per share
Method	Per share
Its own P/E history, lower quartile	$211.10
Its own P/E history, median	$293.24
Its own P/E history, upper quartile	$364.76
52-week range	$265.40 – $444.20
Today	$414.93

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.

On our screens:Cheap stocks by free cash flow yield Quality compounders Quality at a reasonable price R&D leaders

Drug Manufacturers, General

The closest names by size in the same industry